We have recently reported substantial reductions in blood pressure (BP) out to 2 years with renal sympathetic denervation (RDN) in patients with resistant hypertension. However, only a small number of those patients had been followed for 2 years; this report greatly expands the number of patients who reached this timepoint.

Symplicity HTN-I was an open-label cohort study which enrolled 153 patients at sites in Australia, Europe and the United States. Patients were required to have systolic BP ≥160 mm Hg despite at least 3 antihypertensive drugs, including a diuretic, at target or maximal tolerated doses. Patients with an estimated glomerular filtration rate <45 mL/min or type 1 diabetes mellitus were excluded.

Baseline age was 57±11 years, 39% of patients were female, 31% had type 2 diabetes mellitus, eGFR was 83±20 mL/min, heart rate was 73±13 bpm and BP was 176/98±17/15 mmHg, despite use of an average of 5 antihypertensive medications. Change in BP out to 24 months post-RDN procedure is shown in the (Table 1). Additional 30 and 36 month data will be presented. One case of renal artery stenosis was reported at 12 months.

BP progressively declines over 2 years in this much larger current cohort of Symplicity HTN-I patients reaching this timepoint. These findings suggest that functional re-innervation is unlikely to be occurring, at least out to 2 years post-RDN procedure.